POSTER: MPN-161: Benefit of Rusfertide Maintained in Patients With Low-Risk or High-Risk Polycythemia Vera: Efficacy and Safety Subgroup Analysis From the Randomized Controlled Phase 3 VERIFY Study
Year: 2026
Type: article
Authors: Naveen Pemmaraju, Valentín García-Gutiérrez, Aniket Bankar, Kristen M Pettit, Joseph Shatzel, Alessandro Lucchesi, Jiri Mayer, Abdulraheem Yacoub, Harinder Gill, Antonin Hlusi, Daniel Sasca, Joseph M Scandura, David M Ross, Francesca Palandri, Maria Laura Fox, Alessandro Maria Vannucchi, Steffen Koschmieder, Jean-Jacques Kiladjian, Peter Morello, Phillip Dinh, Harinath Reddy Goli, Gregory Vosganian, Sarita Khanna, Arturo Molina, Andrew T Kuykendall
Institutions: The University of Texas MD Anderson Cancer Center, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, University of Michigan, Oregon Health & Science University, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Masaryk University, University of Hong Kong, University Hospital Olomouc, Palacký University Olomouc, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Cornell University, Weill Cornell Medicine, Royal Adelaide Hospital, University of Bologna, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Azienda Ospedaliero-Universitaria Careggi, RWTH Aachen University, Hôpital Saint-Louis, Université Paris Diderot, Protagonist Therapeutics (United States), Moffitt Cancer Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7204686762
FWCI:
Cites:
Cited by:
Related to: